Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: July 20, 2017
| Title: | Preparation of 3-amino(or carbamyl)-5-(pyridinyl)-2(1H)-pyridinones |
| Abstract: | Compounds useful as cardiotonic agents are 1-R-3-Q-5-PY-2(1H)-pyridinones (I) where R is hydrogen, lower-alkyl or lower-hydroxyalkyl, Q is amino (preferred), lower-alkylamino, di-(lower-alkyl)amino or NHAc, Ac is lower-alkanoyl or lower-carbalkoxy, and PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents. The corresponding compounds where Q is nitro, carbamyl, cyano, halo or hydrogen are useful as intermediates and those where Q is hydrogen or cyano also are useful as cardiotonic agents. Said compounds are prepared: by reacting .alpha.-PY-.beta.-(R.sub.1 R.sub.2 N)acrolein (II) with malonamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinamide (Ia) and reacting Ia with a reagent capable of converting carbamyl to amino to produce 3-amino-5-PY-2(1H)-pyridinone (Ib); by reacting II or .alpha.-PY-malonaldehyde (II') with .alpha.-cyanoacetamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinonitrile (III) and partially hydrolyzing III to produce Ia; and, by heating 1,2-dihydro-2-oxo-5-PY-nicotincic acid (IV) with a mixture of concentrated sulfuric acid and concentrated nitric acid to produce 3-nitro-5-PY-2(1H)-pyridinone (Ic) and then either reducing Ic to produce Ib or first reacting Ic with an alkylating agent to produce 1-R'-3-nitro-5-PY-2(1H)-pyridinone (Id) and reducing Id to produce 1-R'-3-amino-5-PY-2(1H)-pyridinone (Ib) where R' is lower-alkyl or lower-hydroxyalkyl. Other derivatives of I where Q is amino are shown. |
| Inventor(s): | Lesher; George Y. (Schodack, NY), Opalka, Jr.; Chester J. (Schodack, NY) |
| Assignee: | Sterling Drug Inc. (New York, NY) |
| Filing Date: | Jun 20, 1979 |
| Application Number: | 06/050,507 |
| Claims: | 1. The process for preparing a 3-Q-5-PY-2(1H)pyridinone having the formula ##STR4## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, and Q is carbamyl or amino, which comprises reacting .alpha.-PY-.beta.-(R.sub.1 R.sub.2 N)acrolein with malonamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinamide and reacting 1,2-dihydro-2-oxo-5-PY-nicotinamide with an alkali metal hypohalite to produce 3-amino-5-PY-2(1H)-pyridinone, where R.sub.1 and R.sub.2 are each lower-alkyl. 2. The process according to claim 1 where PY is 4-pyridinyl and the second step conversion of carbamyl to amino is carried out using bromine and an alkali hydroxide. 3. The process which comprises reacting .alpha.-PY-.beta.-(R.sub.1 R.sub.2 N)acrolein with malonamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinamide having the formula ##STR5## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, and R.sub.1 and R.sub.2 are each lower-alkyl. 4. The process according to claim 3 where PY is 4-pyridinyl. 5. The process which comprises reacting 1,2-dihydro-2-oxo-5-PY-nicotinamide having the formula ##STR6## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, with an alkali metal hypohalite to produce the corresponding 3-amino-5-PY-2-2(1H)-pyridinone. 6. The process according to claim 5 where PY is 4-pyridinyl and the conversion of carbamyl to amino is carried out using bromine and an alkali hydroxide. 7. The process which comprises reacting either .alpha.-PY-.beta.-(R.sub.1 R.sub.2 N)acrolein or .alpha.-PY-malonaldehyde with .alpha.-cyanoacetamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinonitrile and partially hydrolyzing 1,2-dihydro-2-oxo-5-PY-nicotinonitrile to produce 1,2-dihydro-2-oxo-5-PY-nicotinamide having the formula ##STR7## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, and R.sub.1 and R.sub.2 are each lower-alkyl. 8. The process according to claim 7 where PY is 4-pyridinyl. 9. The process which comprises the steps of heating 1-R-1,2-dihydro-2-oxo-5-PY-nicotinonitrile or 1-R-1,2-dihydro-2-oxo-5-PY-nicotinic acid with an aqueous mineral acid to produce 1-R-5-PY-2(1H)-pyridinone, reacting said 1-R-5-PY-2(1H)-pyridinone with halogen to produce the corresponding 1-R-3-halo-5-PY-2(1H)-pyridinone having the formula ##STR8## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen or lower-alkyl and Q is halo, and reacting said 3-halo compound with a lower-alkylamine or a di-(lower-alkyl)amine to produce the corresponding respective 3-(lower-alkylamino)-5-PY-2(1H)-pyridinone or 3-[di-(lower-alkyl)amino]-5-PY-2(1H)-pyridinone. |
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,049 other biopharmaceutical professionals who get our Drug Patent Expiration Alerts:
